Top

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET inhibitors for treating a difficult-to-treat form of lymphoma.

Research findings were published online in Science Translational Medicine.

The study, led by Michael Green, Ph.D., assistant professor of Lymphoma & Myeloma, showed that transcription factor 4 (TCF4) is the most frequent...

Michael Green, Ph.D.

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...

BY Ron Gilmore

A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of Texas MD Anderson Cancer Center demonstrated significantly increased progression-free survival in multiple myeloma patients.

The study, which followed 202 patients, compared busulfan with melphalan versus melphalan alone. Progression-free survival was 65 months for patients receiving combination...

Busulfan and melphalan chemotherapy combination

BY Ron Gilmore

Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income...

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...

BY Ron Gilmore

MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...

BY Ron Gilmore

Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...

BY Ron Gilmore

A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the TRACTION platform inhibits a vital...